Dharamsala News/Low-cost Cancer drug in India; Cadila Pharmaceuticals first to provide it

Dharamsala, November 22, 2013: CMD of Ahmedabad-based Cadila Pharmaceuticals, Dr Rajiv Modi said on Thursday, "Our drug is a significant breakthrough in the management of squamous non-small cell lung cancer (NSCLC), since the introduction of first line cancer drugs nearly 30 years ago."
Cidac-C is an innovative research product for patients suffering from a cancer sub-type - non-small cell lung cancer - and will be priced at Rs 4,000 for 10 injections. The total cost of therapy to patients is estimated at Rs 40,000 - which the company claims is affordable as cancer treatment is generally exorbitant.
Ahmedabad-based Cadila Pharmaceuticals introduced the first novel product for cancer management which it claims is a significant breakthrough in the treatment of lung cancer.